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INTRODUCTION
Genetic thrombophilia is the most common hereditary disorder that increases the likelihood occurrence of thrombosis. It can be identified with a significant minority of patients with venous thromboembolism and in most patients with well-known thrombotic episodes (Murin, Marelich, Arroliga, & Matthay, 1998 ).
There are also other endogenous anticoagulant deficiencies such as Protein C, Protein S and Antithrombin that have been determined to cause hypercoagulable state, but the incidence is low with patients with familial thrombosis. As a result of extensive research and study, it was discovered that resistance to activated protein C (APC) is the most common genetic risk factor for venous thrombosis. It is caused by a single point mutation in the factor V gene. A gene that transcribes the protein called coagulation factor V. These coagulation factors is a group of related proteins that make up the coagulation system that is responsible for the formation of blood clots after an injury and trigger blood vessel repair (Genetics Home Reference, n.d.).
Another important type of hereditary thrombophilia is a variant that occurs in the prothrombin gene at allele 20210 (PT20210), its prevalence and association of thrombosis is not as high compared Factor V Leiden but is significant. The most common clinical manifestation is deep vein thrombosis (DVT) thus, the increased ability to determine underlying risk factors with thrombotic patients will enable to perform immediate testing with these genetic variants.
The detection of the Factor V Leiden mutation and PT20210 allele are best performed using point mutation real-time PCR analysis due to technique simplicity and allows differentiation from rare variants (Peter C. Cooper & Anne C. Goodeve, 2012) . The presence of this mutation will result in a 5-10fold increase for heterozygote carriers and approximately 50 -100fold in homozygotes risk of venous thrombosis which occurs 20-60% of APC resistant individuals. The FV mutation is prevalent from 1-15% in a population of Caucasian origin (Zöller, Hillarp, Berntorp, & Dahlbäck, 1997) .
PROTHROMBIN 20210A MUTATION
The activation of Factor V and Factor VIII by precursor prothrombin converts fibrinogen to fibrin. It has been identified the transition from guanine (G) to adenine (A) at the last nucleotide position 20210 in the 3'-untranslated region of the gene (figure 2) that is associated (Poort SR, 1996) Heterozygotes have a 2-5fold increase risk of thrombosis and with the presence of other forms of thrombophilia will significantly increase thrombotic risk. Homozygotes are rarely occurring in less than 1% of the population.
Historically, laboratory testing for thrombophilia focuses on the detection of the endogenous anticoagulant deficiencies of Protein C, Protein S and Antithrombin, dysfibrinogenemia and antiphospholipid antibodies (APA)/lupus anticoagulants (LA) but for the past decade, venous thromboembolism has been so complex that because of its heterogeneity, diagnosis is dependent on both acquired and genetic factors. In this regard, the mutation determination of FV Leiden and PT20210 gene is highly significant in the pathogenesis of DVT in combination with acquired factors such as trauma, pregnancy, surgery, age, weight, etc.
Coexistence of both mutations of Factor V Leiden and PT 20210 are found in 10% of the population with predetermined thrombotic episodes. (Vicente R et al, 1999) 
VALIDATION STUDY
A combination of 104 whole blood of sodium citrate and EDTA samples that were previously tested using current invader assay method was processed with the GeneXpert technology system. Most of these samples were stored at 2-8C and stable for 15 days and some samples were stored at room temperature with a 24hour stability. Additionally, 15 frozen citrate samples were tested to verify its suitability for testing as recommended by the manufacturer.
Precision studies consist of four (4) Sodium citrate samples consisting of one (1) normal sample for both FV Leiden and PT20210, one (1) heterozygous sample for PT20210, one (1) heterozygous sample for FV Leiden and one (1) homozygous sample for both FV Leiden and PT20210. These 4 samples were run in duplicate for 5 days.
Correlation studies were performed with eighty-five (85) whole blood samples, a combination of sixty-four (64) citrate tubes and twenty-one (21) EDTA samples. The samples included two (2) homozygous FV Leiden, one (1) homozygous PT20210, thirty-seven (37) Heterozygous FV Leiden, thirty-one (31) normal FV Leiden, seventeen (17) heterozygous PT20210 and fifty-one (51) normal PT20210. Fifteen (15) frozen citrate samples were also tested for possible consideration of using this type of sample for testing as stated by the manufacturer.
INDIVIDUALIZED QUALITY CONTROL PLAN
According to the Clinical Laboratory Improvement Amendments (CLIA) of 1988, laboratories are required to have Quality Control procedures to monitor the accuracy and reliability of test results. A minimum of 2 levels of controls must be performed every eight hours of patient testing. IQCP provides a foundation for an alternative quality control (QC) program that would allow laboratories, after appropriate assessment, the choice to implement a 6 customized QC plan for specific tests utilizing internal control systems. By performing the steps of IQCP, it will evaluate the potential sources of error in the three (3) phases of testing and establish an appropriate QC and best practices to prevent possible errors. After the evaluation process, other potential sources of error might be determined and that may require additional QC activities resulting in a more comprehensive QC program.
IQCP consists of 3 parts: Risk assessment (RA), Quality control plan (QCP) and Quality Assessment (QA).
1.RISK ASSESSMENT (RA)
Identification and evaluation of the risk that occurs in the preanalytical, analytical and post-analytical phases of testing. There are six (6) components that need to be evaluated for Risk assessment for potential sources of error and possible failures. These are Specimen, Test System, Reagents, Environment, Testing personnel, and Test results. Based on the information listed, a table summary of Risk assessment (Table 7) was established for possible sources of error or failures consisting of the six (6) elements in relation to the different phases of testing. It is evaluated according to Risk level (Table 1) and Risk acceptability (Table 2) . 
Lists of information to conduct
COSTS SAVING
Preventive Maintenance cost-The elimination of seven (7) instruments that includes two (2) EZ instruments for DNA isolation, three (3) thermal cyclers for amplification and two (2) Tecan readers for sample detection will save an estimated amount of $10,000.00 per year for preventive maintenance cost and other additional expense for other instrumentation problems. 
DISCUSSION
Thrombophilia is defined as an increased risk or tendency to develop blood clots as a result of predisposing factors that may be inherited or acquired. It is usually related to the abnormality of the clotting system of some individuals causing DVT or pulmonary embolism.
The determination of both Factor V Leiden and PT20210 mutation using GeneXpert technology gives molecular testing a different perspective from usual standard PCR testing. The test is moderately complex, but the assay is a simple 2 step process that it can be performed by personnel with less background in molecular testing. It is a fast, single test assay that eases workflow and delivers same day test results to the clinicians. The technology allows flexibility to perform other tests for the benefit of better patient management and treatment.
With the approval of the laboratory medical director for the IQCP implementation, the risk assessment analysis reinforces the accuracy of test results thru the detection of possible sources of error throughout the three (3) phases of testing. It is enhanced by a customized quality control plan and a comprehensive quality assessment that will be reviewed and monitored as indicated in the QC and QA summary. All necessary corrective action will be applied and implemented to mitigate prevent failures and probable sources of error.
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CONCLUSION
Given its heterogeneity of clinical expressions and still lack of gold standard of testing, the Cepheid GeneXpert technology will improve the management of individuals who have the greatest probability of having venous thromboembolism caused by the genetic mutations of Factor V Leiden and PT20210 variants. Result turnaround time is reduced to 24hrs, prevents potential staff injury from repetitive motion and promote cost saving for labor and instrument maintenance.
